First AD

Second AD

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Role of ADCs in HER2-Mutated NSCLC

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC

Peer Exchange

City of Hope

Cancer Centers

Partner

UC San Diego Health Moores Cancer Center

University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center

Diagnosing HER2-mutated NSCLC

Biomarker Testing Challenges in HER2-mutated NSCLC

DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC